Slide 1: Investor Presentation March 2022
INVESTORpresentation March 2022 Ofer Haviv, President & CEO
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or
Slide 3: Agenda
Agenda IntroductionFields of activityMain subsidiariesSummary 3 Annex I - TechnologyAnnex II - Financial Fundamentals
Slide 4: Our Vision: Decoding Biology
Our Vision 4 DECODING BIOLOGY Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.
Slide 5: Life-science product development
Life-science product development Low probability of success with high cost and long time-to-market Pharmaceutical Industry Ag-chemicalsIndustry In the 1970’s 2000’s – 2017 $180 million Cost of developing a single pharmaceutical drug $2.7 billion Time to develop a new crop protection product 1995 200
Slide 6: Life-science product development: needle in the haystack
Life-science product development The ultimate case of a needle in the haystack Regulation Development Optimization Discovery Agriculture xxx xxx Pharma 6 ApprovedProduct Product Candidates The challenge: Finding the winning candidates out of a vast number of possible prospects, that address a comple
Slide 7: The opportunity
Utilizing an advanced computational biology platform, to identify the most promising candidates addressing multiple development challenges, towards successful life-science products:Increase probability of success Reducing time and cost 7 HUMAN HEALTH Agriculture Other Industries The opportunity
Slide 8: When biology meets disruptive technologies
When biology meetsdisruptive technologies platform 8 BIG DATA BIOLOGY AI Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), to successfully discover & guide the development of novel life-science based products. – Computational
Slide 9: Tailor-made Engines for product discovery & development
Tailor-made Engines for product discovery & development The CPB platform enhances product discovery and development through dedicated Engines for products based on three core components:MicrobesSmall molecules Genetic elements 9 MICROBES GENETIC ELEMENTS SMALL MOLECULES
Slide 10: Case Study – Potential uses for MicroBoost AI
10 AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES PlasticDegradation Chemicals Source forEnzymes Oil SpillClearing WastewaterTreatments Microbialsfor Crops Food Human &Animal Probiotics Therapeuticmicrobials Probiotics DietarySupplements Developing an eco-system around our tech engines Case S
Slide 11: a Micro
a Micro S2/300st"' User Interface 6,650,502 200,599,577 SQ 93,995 evOgel DECODING BIOLOGY +
Slide 12: Product-oriented subsidiaries powered by Evogene's technology
Product-oriented subsidiaries powered by Evogene’s technologyEstablish independent entities focusing on a defined commercial field with an exclusive license to use Evogene’s unique solutions for product development. 12 Business Model Microbiome based therapeutics Medical cannabis Ag-solutions for ca
Slide 13: Business Model: Collaborations
13 Business Model Collaborations powered by Evogene’s technology for the development of innovative productsJoint development with leading companies for defined products utilizing Evogene’s unique solution. Typically, partner leads later-stage development and product commercialization. 2 Powered by E
Slide 14: Agenda
Agenda IntroductionFields of activityMain subsidiariesSummary 14 Annex I - TechnologyAnnex II - Financial Fundamentals
Slide 15: Current life-science based products powered by Evogene's tech-engines
15 Current life-science based products powered by Evogene’s tech-engines OTHER INDUSTRIES AGRICULTURE HUMAN HEALTH Ag-Biologicals MicrobiomebasedTherapeutics MICROBES Ag-Chemicals Drugs based on small molecules SMALL MOLECULES Ag-solutionsfor castoroil production Seed Traits MedicalCannabis GENETIC
Slide 16: OTHER INDUSTRIES AGRICULTURE HUMAN HEALTH MICROBES SMALL MOLECULES GENETIC ELEMENTS Seed Traits [division] *
16 OTHER INDUSTRIES AGRICULTURE HUMAN HEALTH MICROBES SMALL MOLECULES GENETIC ELEMENTS Seed Traits [division] * * Non-exclusive license Development & commercialization through subsidiaries and collaborations
Slide 17: Evogene Group
Evogene Group 17 *Evogene holdings Other Industries 100%* Castor Oil ProductionCastor seeds &growth protocols HumanHealth Microbiome basedTherapeuticsImmuno-oncologyGI- gastrointestinal- related disordersMDRO – multi-drug resistant organisms Medical CannabisHigh yield & consumer traitsTherapeutic tr
Slide 18: Industry Landscape
Microbiome Based Therapeutics Medical Cannabis Ag-Biologicals Ag-Chemicals Company Name Market Cap/Funds Raised Company Name Market Cap/Funds Raised Company Name Market Cap/Funds Raised Company Name Market Cap/Funds Raised $166m* $1.6B* Raised $116m# (Sep 2021) Raised $24m#(Jan 2017) $320m* $4.3B* €
Slide 19: Agenda
Agenda IntroductionFields of activityMain subsidiariesSummary 19 Annex I - TechnologyAnnex II - Financial Fundamentals
Slide 20: Microbiome Based Therapeutics
20 Immuno-oncology program:Combination therapy for cancer with checkpoint inhibitorsPre-clinical stageAddressable market size expected by 2026* – $243BGI related disorders:Inflammatory Bowel Disorder (IBD) – pre-clinical stageIrritable Bowel Syndrome (IBS) – discovery stageAddressable market size ex
Slide 21: Example Results: BMC128 improved antitumor activity
21 Example Results: Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo | Human Microbiome
Slide 22: Medical Cannabis Product Pipeline
22 MetaYield+ Products:Stable enhancement of total plant compounds:Increased compounds per plantIncreased compounds per areaTotal Cannabis market size expected by 2024 – $42.7B* Precise+ Products:Stable enhancement of specific active compounds for pain and inflammation: Medical indication focusCompo
Slide 23: First Products: Medical Cannabis
23 First Products: Medical Cannabis aiming at high THC, high yield, big inflorescence and dense trichomes MetaYield products– increased compounds per area, addressing the T20/C4 (17%-24% THC & 1%-7% CBD) and T15/C3 (11%-19% THC & 0.5%-5.5% CBD) market segments. | Medical Cannabis
Slide 24: Ag-Chemicals Product Pipeline
24 Herbicides:Novel MoA (Mode-of-Action) selective/non-selective herbicidesRelevant target crops – Cereals, Rice, Corn, Soybean, Cotton, Canola, Sugar Beet, Other TBDAddressable market size expected by 2022*: $34BLead stage Insecticides:Novel SoA (Site-of-Action)Addressable market size expected by 2
Slide 25: Example Results: New MoA Herbicide APH1
25 Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1 | Ag-Chemicals Greenhouse testing of APH1 – modified tobacco plants with resistance trait vs unmodified control (weed) Example Results: New MoA Herbicide - APH1
Slide 26: Ag-Biologicals
26 | Ag-Biologicals Bio-stimulants (yield enhancement):Bio-stimulants 1– focus on wheat and additional cereals. Seed treatment/soil application. Commercial stage, first sales planned in 2022. Addressable market size*: for spring wheat ±25M acres.Bio-stimulants 2 – focus on corn and additional crops.
Slide 27: Ag-Biologicals Example Results
27 | Ag-Biologicals Example of treatment against Botrytis Cinerea in vines – untreated control vs treated vines Lavie Bio’s wheat field in the USA during harvest – initial sales in 2022 Example Results: - result™ inoculant (bio-stimulant)- LAV 311 & LAV 312 leading bio-fungicide candidates for fruit
Slide 28: Expected main near-term value drivers
SubsidiariesExpected main near-term value drivers 2022 2023 IBD – initiate scale-up for GMP production of drug candidate for IBD Immuno-oncology – readout from proof-of-concept, first in human study IBD – clinical batch production of drug candidate for IBD as preparation for Phase 1 clinical trials
Slide 29: Agenda
Agenda IntroductionFields of activityMain subsidiariesSummary 29 Annex I - TechnologyAnnex II - Financial Fundamentals
Slide 30: Employees
140 30 30 56 Employees % PhDs % Women Computational systems biology Molecular biology Genetics Computational chemistry Microbiology Biochemistry Bioinformatics Incl. chairpersonof the board
Slide 31: Summary
31 Summary Our vision - Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies. CPB platform - a unique technology platform stemming from the incorporation of deep scientific understandings of biology together with big-data and a
Slide 32: Thank You!
THANK You!
Slide 33: Annex I: Technology
Annex I: Technology evOgene DECODING BIOLOGY + 33
Slide 34: The challenge in creating life-science based products
34 Efficacy Safety Selectivity Shelf-life Other ProductLaunch Candidate Selection ProductDefinition Discovery Development The challenge in creatinglife-science based products
Slide 35: The challenge in creating life-science based products
35 Candidate Selection ProductDefinition Common practiceDiscovery – selection of product candidates mainly addressing efficacy The challenge in creatinglife-science based products Efficacy Safety Selectivity Shelf-life Other ProductLaunch
Slide 36: The challenge in creating life-science based products
36 Candidate Selection ProductDefinition Low probability of successLong time to marketHigh development costs Development – inefficient optimization & difficulty in addressing a single challenge without impairing others The challenge in creatinglife-science based products Efficacy Safety Selectivity
Slide 37: Evogene's AI-based solution: Discovery
Evogene’s AI-based solution:Discovery 37 Candidate Selection ProductDefinition A multi-attribute computational selection of product candidates, addressing relevant challenges using dedicated training data sets and AI. Efficacy Safety Selectivity Shelf-life Other ProductLaunch
Slide 38: Evogene's AI-based solution: Development
Evogene’s AI-based solution:Development 38 Candidate Selection ProductDefinition A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes. Efficacy Safety Selectivity Shelf-life
Slide 39: Evogene's AI engines provide tailor-made solutions
39 Evogene’s AI engines provide tailor-made solutions Development Computational driven solution for guiding and assessing the optimization process of the selected core component, without impairing other key product attributes. DiscoveryComputational prediction of candidates, to serve as the product’
Slide 40: Annex II: Financial Fundamentals
Annex II:Financial Fundamentals 40
Slide 41: Key Financials: Balance Sheet
Key Financials:Balance Sheet Key Points:Consolidated cash position: ~$54 million as of 31.12.2021, of which ~$8 million is appropriated to Lavie BioNo bank debtListed on TASE (2007) and NASDAQ (2016) 1 Thousands of US $ 31.12.2021 31.12.2020 Current Assets 56,890 51,823 Long-Term Assets 19,414 20,09